BioCryst Pharmaceuticals | BCRX - 净收入



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 2.03B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


净收入 更改 日
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Chugai Pharma JPY 115.42B 12.99B 2026-03
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
DBV Technologies USD -47.6M 2.77M 2026-03
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Gilead Sciences USD 2.02B 162M 2026-03
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Glaxosmithkline GBP 1.74B 890.94M 2026-03
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Novavax USD 17.53M 219.91M 2025-12
PTC Therapeutics USD -2.81M 132.16M 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03